Peramivir Susceptibilities of Recombinant Influenza A and B Variants Selected with Various Neuraminidase Inhibitors

Molinari N.A. , Ortega-Sanchez I.R. , Messonnier M.L. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25: 5086–5096.

Samson M. , Pizzorno A. , Abed Y. , Boivin G. Influenza virus resistance to neuraminidase inhibitors. Antiviral Res 2013; 98: 174–185.

Wester A. , Shetty A.K. Peramivir injection in the treatment of acute influenza: a review of the literature. Infect Drug Resist 2016; 9: 201–219.

Zaraket H. , Saito R. Japanese surveillance systems and treatment for influenza. Curr Treat Options Infect Dis 2016; 8: 311–328.

Yoshida R. , Kida H. , Sugaya N. Neuraminidase sequence analysis and susceptibility to peramivir of influenza viruses isolated from clinical trials. XV International congress of virology IUMS. 11–16 September 2011, Sapporo, Japan.

Nguyen H.T. , Fry A.M. , Loveless P.A. , Klimov A.I. , Gubareva L.V. Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/ I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010; 51: 983–984.

Dapat C. , Kondo H. , Dapat I.C. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009–2010 and 2010–2011 influenza seasons in Japan. Antiviral Res 2013; 99: 261–269.

Monto A.S. , McKimm-Breschkin J.L. , Macken C. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50: 2395–2402.

Hurt A.C. , Chotpitayasunondh T. , Cox N.J. Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives. Lancet Infect Dis 2012; 12: 240–248.

Yen H.L. , Hoffmann E. , Taylor G. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. J Virol 2006; 80: 8787–8795.

Richard M. , Ferraris O. , Erny A. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir. Antimicrob Agents Chemother 2011; 55: 2942–2952.

Baz M. , Abed Y. , McDonald J. , Boivin G. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 2006; 43: 1555–1561.

Sleeman K. , Mishin V.P. , Guo Z. Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013. Antimicrob Agents Chemother 2014; 58: 2045–2051.

Burnham A.J. , Baranovich T. , Marathe B.M. , Armstrong J. , Webster R.G. , Govorkova E.A. Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother 2014; 58: 2718–2730.

FDA. Tamiflu - full prescribing information. Food and Drugs Administration 2013; 1–28. (Updated May 2014. Accessed 8 September 2017.) Available from www.accessdata.fda.gov/drugsatfda_docs/label/2014/021087s064,021246s047lbl.pdf.

Hatakeyama S. , Sugaya N. , Ito M. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 2007; 297: 1435–1442.

Tai C.Y. , Escarpe P.A. , Sidwell R.W. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Agents Chemother 1998; 42: 3234–3241.

McSharry J.J. , McDonough A.C. , Olson B.A. , Drusano G.L. Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors. Clin Diagn Lab Immunol 2004; 11: 21–28.

Baum E.Z. , Wagaman P.C. , Ly L. A point mutation in influenza B neuraminidase confers resistance to peramivir and loss of slow binding. Antiviral Res 2003; 59: 13–22.

Liu Q. , Wang S. , Ma G. Improved and simplified recombineering approach for influenza virus reverse genetics. J Mol Genet Med 2009; 3: 225–231.

Zhou B. , Lin X. , Wang W. Universal influenza B virus genomic amplification facilitates sequencing, diagnostics, and reverse genetics. J Clin Microbiol 2014; 52: 1330–1337.

Samson M. , Abed Y. , Desrochers F.M. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir. Antimicrob Agents Chemother 2014; 58: 5220–5228.

Hoffmann E. , Neumann G. , Kawaoka Y. , Hobom G. , Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000; 97: 6108–6113.

Kiso M. , Kubo S. , Ozawa M. Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses. PLoS Pathog 2010; 6: e1000786.

Boivin G. , Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res 2002; 54: 143–147.

Okomo-Adhiambo M. , Sheu T.G. , Gubareva L.V. Assays for monitoring susceptibility of influenza viruses to neuraminidase inhibitors. Influenza Other Respir Viruses 2013; 7 Suppl 1: 44–49.

Nguyen H.T. , Sheu T.G. , Mishin V.P. , Klimov A.I. , Gubareva L.V. Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010; 54: 3671–3677.